Research graph
References from HIMALAYA: learning from another negative phase 2 trial in ALS. Local targets link to admitted publications; unresolved targets remain external evidence.
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis
10.1016/s1474-4422(21)00465-8 · 2022 · External reference
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis
10.1016/s1474-4422(21)00414-2 · 2022 · External reference
TDP-43: [GU]-ardian of the transcriptome
10.1186/s13024-026-00944-2 · 2026 · External reference
Rodent models of amyotrophic lateral sclerosis
10.1002/0471141755.ph0567s69 · 2015 · External reference
Single-cell transcriptomic and functional studies identify glial state changes and a role for inflammatory RIPK1 signaling in ALS pathogenesis
10.1016/j.immuni.2025.02.024 · 2025 · External reference
RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS
10.1126/science.aaf6803 · 2016 · External reference
Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants
10.1111/cts.13690 · 2024 · External reference
10.1016/s1474-4422(26)00277-2 · 2026 · Admitted local publication
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
10.1016/s1474-4422(24)00134-0 · 2024 · External reference
Amyotrophic lateral sclerosis: a lesson in translation
10.1016/s1474-4422(24)00223-0 · 2024 · External reference
PRECISION ALS: an integrated pan European patient data platform for ALS
10.1080/21678421.2023.2215838 · 2023 · External reference
